Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Publisher Name :
Date: 01-Nov-2016
No. of pages: 100
This report is available at upto 40% Discount. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's Report, "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Report is to understand the market and pipeline status of the drugs around the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight's Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). While the leading brands, companies and chemicals are considered thoroughly, DelveInsight's report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Scope:

- A snapshot of the global Market and Phase III therapeutics scenario for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).

- A review of the marketed products under prescription for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), regulatory information and marketing status.

- Coverage of global patent coverage and detailed commentaries on the US patent challenges.

- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

- Product profiles for marketed products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

- Coverage of API Manufacturers for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) drugs in the United States, Europe and Asian Regions with location details.

- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) drugs.

- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) drugs.

- Coverage of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

- Key discontinued Marketed products.

- Global Sales Figure to 2018.

Reasons to buy

- Evaluate the marketing status and exclusivity details of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) key products to exploit opportunities for generic drug development opportunities.

- Identify and understand important and diverse types of therapeutics under Phase III development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).

- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).

- API intelligence over marketed drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and gaining primary intelligence over active ingredients manufacturers across the globe.

- API intelligence over leading Phase III Pipeline drugs.

- Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

- Understanding the scope of the Phase III Drugs with nil regulatory filings.

- Understanding the chemical route of synthesis of approved drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).

- Uncovering opportunities in the rapidly growing US market.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Table of Contents

1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, Marketed Drugs by Application Type, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, (Year), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Marketed Drugs, API Manufacturers by US DMF Status, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, Europe by Country, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, India by State, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, China by Province, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers by Geography 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, Global Sales-2018 (in million USD)
API Manufacturers for Drug, 2016
Phase III Drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2016
Discontinued Drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), 2016

List of Figures

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, US, (Year), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Marketed Drugs, US DMF Status Drug Specific (Number), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, Europe by Country, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, India by State, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers, China by Province, 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs, API Manufacturers by Geography 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutic Market, Global Sales 2018 (in million USD)
Drug, Patent/Exclusivity Expiry (Year), 2016
  • Global Letrozole Market Professional Survey Report 2016
    Published: 02-Dec-2016        Price: US 3500 Onwards        Pages: 106
    Notes: Production, means the output of Letrozole Revenue, means the sales value of Letrozole This report studies Letrozole in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manuf......
  • Global Tamoxifen Sales Market Report 2016
    Published: 02-Dec-2016        Price: US 4000 Onwards        Pages: 106
    Notes: Sales, means the sales volume of Tamoxifen Revenue, means the sales value of Tamoxifen This report studies sales (consumption) of Tamoxifen in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Teva - Yangtze River Pharmaceutical Group - Chemische Fabrik Berg - PCAS - Suzho......
  • Global Thyroid Cancer Drug Sales Market Report 2016
    Published: 02-Dec-2016        Price: US 4000 Onwards        Pages: 105
    Notes: Sales, means the sales volume of Thyroid Cancer Drug Revenue, means the sales value of Thyroid Cancer Drug This report studies sales (consumption) of Thyroid Cancer Drug in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Abott Laboratories - Genzyme - Eisai - Pfizer - La......
  • Global Paclitaxel Market by Manufacturers, Regions, Type and Application, Forecast to 2021
    Published: 01-Dec-2016        Price: US 3480 Onwards        Pages: 117
    Paclitaxel is a mitotic inhibitor used in cancer chemotherapy; Paclitaxel was discovered in 1962 as a result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it taxol.Paclitaxel is a white crystalline powder, odorless and tasteless. It is insoluble in water and soluble in chloroform, acetone and other organic solvents.Scope of the Report:This report ......
  • Global Capecitabine Sales Market Report 2016
    Published: 30-Nov-2016        Price: US 4000 Onwards        Pages: 104
    Notes: Sales, means the sales volume of Capecitabine Revenue, means the sales value of Capecitabine This report studies sales (consumption) of Capecitabine in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Roche - Tecoland - ScinoPharm - Aarti Group - Cipla - Intas......
  • United States Malignant Melanoma Drug Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Malignant Melanoma Drug Revenue, means the sales value of Malignant Melanoma Drug This report studies sales (consumption) of Malignant Melanoma Drug in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - Enzon Pharmaceuticals - Exelixis - GlaxoSmithKline - Merck - Navidea Biopharmaceuticals......
  • Global Prostate Cancer Drugs Market 2016-2020
    Published: 29-Nov-2016        Price: US 2500 Onwards        Pages: 91
    Prostate cancer is the cancer of prostate gland. According to CDC, it is one of the leading cause of cancer death in men across the races in the US. According to the Urology Care Foundation, globally, one in seven men will be diagnosed with the disease. About one in 35 men die due to prostate cancer. Growth in the prostate can be benign or malignant. Prostate cancer cells spread by breaking away from a prostate tumor. They may travel through blood vessels or lymph vessels and reach other part......
  • Europe Lentinan Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 124
    Notes: Sales, means the sales volume of Lentinan Revenue, means the sales value of Lentinan This report studies sales (consumption) of Lentinan in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Ajinomoto - Elicityl - Nammex - Panjin Gerun Biotech - Golden Horizon B......
  • Europe Doxorubicin Market Report 2016
    Published: 28-Nov-2016        Price: US 3900 Onwards        Pages: 101
    Notes: Sales, means the sales volume of Doxorubicin Revenue, means the sales value of Doxorubicin This report studies sales (consumption) of Doxorubicin in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Pfizer - Johnson & Johnson - Sun Pharmaceutical Industries - Meiji Se......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs